(Reuters) – German healthcare group Fresenius beat second-quarter operating profit expectations on Wednesday, citing strong performance at its Kabi and Helios units, and progress in group-wide cost savings.
It reported earnings before interests and taxes (EBIT) of 660 million euros ($714 million), up 16% from a year ago.
Analysts were expecting an EBIT of 636 million euros, according to a consensus of forecasts from Vara Research.
“Cash came in extremely strong, materially improving our financial profile. We are well ahead of our plans to de-leverage and to take out costs,” CEO Michael Sen said in a statement.
Fresenius reported a quarterly net loss of 373 million euros, compared to a profit of 80 million euros a year ago, due to effects related to the discontinued operations at its loss-making service unit Vamed.
In May, the company said it had completed its restructuring with a “structured exit” from Vamed.
Fresenius confirmed its full-year EBIT guidance of a 6-10% growth, and said it is now confident of reaching the upper half of this range.
($1 = 0.9239 euros)
(Reporting by Bartosz Dabrowski in Gdansk; Editing by Varun H K and Janane Venkatraman)
Comments